Last reviewed · How we verify
NCT03703401
The Role of Hydrosalpinx in Recurrent Miscarriage
trial testing Hysterosalpingo-contrast-sonogram in Abortion, Spontaneous in 137 participants. Completed in 15 January 2021.
11 September 2020
Quick facts
| Lead sponsor | University of Birmingham |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 137 |
| Start date | 28 February 2018 |
| Primary completion | 11 September 2020 |
| Estimated completion | 15 January 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Hysterosalpingo-contrast-sonogram
Conditions studied
- Abortion, Spontaneous — all drugs for Abortion, Spontaneous →
- Miscarriage, Recurrent — all drugs for Miscarriage, Recurrent →
- Hydrosalpinx — all drugs for Hydrosalpinx →
Sponsor
University of Birmingham
Who can join
Adults 18 to 45, female only, with Abortion, Spontaneous or Miscarriage, Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Miscarriage affects one in five pregnancies and little progress has been made in understanding and treating this distressing condition. C. trachomatis is the most common sexually transmitted infection in the UK. C. trachomatis infection can have serious health consequences, including fallopian tube damage. Untreated C. trachomatis infection and tubal damage have been associated with miscarriage and adverse pregnancy outcomes such as preterm birth, low birth weight and stillbirth. A cohort study is needed to establish the prevalence of tubal disease in women with recurrent miscarriages. HyCoSy will be performed to identify tubal disease and establish the magnitude of the problem in the recurrent miscarriage population. The prognosis of tubal disease on miscarriage and other obstetric outcomes, and the role of medical interventions such as tubal surgery (to treat hydrosalpinx) on reducing miscarriage and adverse obstetric outcomes will also be studied. Objectives 1. Establish the prevalence of hydrosalpinx in the recurrent miscarriage population. 2. Establish the prognosis of women diagnosed with recurrent miscarriage with concurrent hydrosalpinx. 3. Explore the role of tubal surgery for improving reproductive outcomes in women with recurrent miscarriage population and hydrosalpinx.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03703401
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Abortion, Spontaneous
Currently open trials in the same condition.
- NCT05516810 — The Accuracy of Ultrasound Diagnosis of Hydatidiform Moles · active not recruiting
Other University of Birmingham trials
Trials by the same sponsor.
- NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
- NCT07446166 — TETANUS Antibody Detection in Saliva Study · NA · not yet recruiting
- NCT07294794 — Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension · NA · not yet recruiting
- NCT07246356 — Feasibility and Efficacy of GTEP for Birth Trauma · NA · recruiting
- NCT06932653 — Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03703401 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Birmingham
- Last refreshed: 16 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03703401.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing